Poulton Stuart (CIK 1942597) reported 13 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-05-15). Recent activity: Sell KPTI (403 shares), Buy KPTI (896 shares), Sell KPTI (5,101 shares), Sell KPTI (378 shares), Buy KPTI (32,415 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-15 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Sell | 403 | $3,828 |
| 2026-05-15 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Buy | 896 | $0 |
| 2026-03-03 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Sell | 5,101 | $48,000 |
| 2026-02-19 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Sell | 378 | $3,262 |
| 2026-02-03 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Buy | 32,415 | $0 |
| 2025-10-16 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Buy | 39,682 | $0 |
| 2025-09-16 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Buy | 888 | $0 |
| 2025-09-16 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Sell | 401 | $2,578 |
| 2025-07-30 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Sell | 191 | $835 |
| 2025-03-06 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Sell | 3,548 | $22,317 |
| 2025-03-04 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Buy | 5,000 | $0 |
| 2025-03-04 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Buy | 4,583 | $0 |
| 2025-02-19 | Karyopharm Therapeutics Inc. (KPTI) | EVP, Chief Development Officer | Sell | 5,914 | $0 |
Source: SEC Form 4 filings · as of 2026-05-15